Procalcitonine als biomarker voor infecties

Translated title of the contribution: Procalcitonin as biomarker for infections

J C de Jonge, D W de Lange, E A Bij de Vaate, H van Leeuwen, J E Arends

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

- Inappropriate use of antibiotics in patients without bacterial infection contributes significantly to worldwide antibiotic resistance.- The goal of this review is to summarise evidence from randomised trials investigating the value of the biomarker procalcitonin (PCT) in patients with symptoms of a bacterial infection in the emergency department (ED) and intensive care (IC).- In patients with a lower respiratory infection in the ED, RCTs demonstrate that withholding or shortening of antibiotic treatment in patients with low PCT levels does not lead to a change in clinical outcome. Similar results were observed in IC patients, where a reduction in PCT level indicates that antibiotics can be discontinued sooner.- In conclusion, initiating and discontinuing antibiotics in ED and IC patients based on PCT levels is safe, appears cost-saving and leads to a reduction in antibiotic use due to fewer antibiotics prescriptions and shortened courses.

Translated title of the contributionProcalcitonin as biomarker for infections
Original languageDutch
Article numberD282
JournalNederlands Tijdschrift voor Geneeskunde
Volume160
Issue number44
Publication statusPublished - 2016

Fingerprint

Dive into the research topics of 'Procalcitonin as biomarker for infections'. Together they form a unique fingerprint.

Cite this